In this episode of Deep Tech Talk, Chris delves into the technical advancements of MRD (Minimal Residual Disease) testing in oncology. Explore the precision of next-gen sequencing and digital PCR in detecting microscopic traces of cancer post-treatment. Learn about industry leaders like F. Hoffmann-La Roche, Guardant Health, and Adaptive Biotechnologies, and the role of MRD testing in personalized medicine and early relapse detection. Tune in for an in-depth look at the future of precision cancer diagnostics. 

 #MRDTesting #MinimalResidualDisease #CancerCare #PrecisionOncology #NextGenSequencing #DigitalPCR #CancerDetection #OncologyInnovation #PersonalizedMedicine #LiquidBiopsy #AdaptiveBiotechnologies #GuardantHealth #FhoffmannLaRoche #EarlyDetection #CancerResearch #OncologyTech #DeepTech #TechInMedicine #HealthTech #FutureOfCancerCare